A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.

Saved in:
Bibliographic Details
Title: A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
Authors: Shahswar R; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Gabdoulline R; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Krueger K; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Wichmann M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Götze KS; Department of Medicine III, Technical University of Munich (TUM) School of Medicine and Health, Munich, Germany.; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany., Braitsch K; Department of Medicine III, Technical University of Munich (TUM) School of Medicine and Health, Munich, Germany., Meggendorfer M; MLL, Munich Leukemia Laboratory, Munich, Germany., Schmalbrock L; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Bullinger L; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Modemann F; Department of Oncology, Hematology and Bone Marrow Transplantation, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Fiedler W; Department of Oncology, Hematology and Bone Marrow Transplantation, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Krauter J; Department of Internal Medicine, Municipal Hospital Braunschweig, Braunschweig, Germany., Kaun S; Department of Internal Medicine, Municipal Hospital Bremen-Mitte, Bremen, Germany., Rotermund S; Department of Internal Medicine, Municipal Hospital Bremen-Mitte, Bremen, Germany., Voß A; Department of Oncology and Hematology, University Clinic Oldenburg, Oldenburg, Germany., Behrens YL; Department of Human Genetics, Hannover Medical School, Hannover, Germany., Bergmann AK; Department of Human Genetics, Hannover Medical School, Hannover, Germany., Koller E; 3rd Medical Department, Hanusch Hospital, Vienna, Austria., Beutel G; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Thol F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Heidel F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. innere4@uk-halle.de.; Department of Internal Medicine IV, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany. innere4@uk-halle.de.
Source: Leukemia [Leukemia] 2025 Mar; Vol. 39 (3), pp. 614-622. Date of Electronic Publication: 2025 Jan 08.
Publication Type: Journal Article; Multicenter Study; Observational Study
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-024-02501-6